98751-79-2

Usage

Uses

Used in Pharmaceutical Industry:
Paeonilactone A is used as a potential therapeutic agent for neurodegenerative diseases due to its neuroprotective properties. It may help in the treatment and management of conditions such as Alzheimer's disease, Parkinson's disease, and other related disorders by protecting neurons from damage and degeneration.
Used in Anti-inflammatory Applications:
Paeonilactone A is used as an anti-inflammatory agent for the treatment of inflammatory conditions. Its anti-inflammatory properties can help reduce inflammation and alleviate symptoms associated with various inflammatory diseases, such as arthritis, asthma, and inflammatory bowel disease.
Used in Antioxidant Formulations:
Paeonilactone A is used as an antioxidant in health and wellness products. Its antioxidant effects can help neutralize free radicals, protect cells from oxidative damage, and contribute to overall health and well-being.
Used in Drug Development:
Paeonilactone A is used as a lead compound in the development of new drugs for various medical conditions. Its diverse biological activities and potential therapeutic effects make it a valuable candidate for further research and drug development.

Upstream product

• 124618-15-1 (3S,3aS,5S,6R,7aS)-5,6-Dihydroxy-3,6-dimethyl-hexahydro-benzofuran-2-one 
• 124618-15-1 (3R,3aR,5R,6S,7aR)-5,6-dihydroxy-3,6-dimethylhexahydrobenzofuran-2-one 
• 99-48-9 (4R,6R)-carveol 
• 7111-29-7 (1R-cis)-2-methyl-5-(1-methylethenyl)-2-cyclohexen-1-ol acetate 
• 124618-13-9 (3aR,4R,4aS,7aR,8aR)-4-Iodo-3a,7-dimethyl-2-trichloromethyl-hexahydro-furo[2',3':4,5]benzo[1,2-d][1,3]dioxol-6-one 
• 24120-79-4 (1R,2R,4S,6S)-(-)-1-methyl-4-(prop-1-en-2-yl)-7-oxabicyclo[4.1.0]heptan-2-ol 
• 139685-65-7 (3aS,4aR,7R,7aR,8aR)-2,2,3a,7-Tetramethyl-hexahydro-furo[2',3':4,5]benzo[1,2-d][1,3]dioxol-6-one 
• 139685-64-6 (3aS,4aR,7S,7aR,8aR)-2,2,3a,7-Tetramethyl-hexahydro-furo[2',3':4,5]benzo[1,2-d][1,3]dioxol-6-one 
• 139618-30-7 (3aR,4R,6S,7aR)-6-Isopropenyl-2,2,3a-trimethyl-4-phenylselanyl-hexahydro-benzo[1,3]dioxole 
• 139618-33-0 (3aR,4R,4aS,7aR,8aR)-4-Iodo-2,2,3a-trimethyl-7-methylene-hexahydro-furo[2',3':4,5]benzo[1,2-d][1,3]dioxol-6-one 
• 139618-32-9 2-((3aR,5S,7aS)-2,2,7a-Trimethyl-3a,4,5,7a-tetrahydro-benzo[1,3]dioxol-5-yl)-prop-2-en-1-ol 
• 139685-63-5 (3aS,4aR,7aR,8aR)-2,2,3a-Trimethyl-7-methylene-hexahydro-furo[2',3':4,5]benzo[1,2-d][1,3]dioxol-6-one 
• 139618-31-8 (3aR,5S,7aS)-2,2,7a-Trimethyl-5-(2-methyl-oxiranyl)-3a,4,5,7a-tetrahydro-benzo[1,3]dioxole 
• 124618-09-3 2-((1R,5R)-5-Acetoxy-4-methyl-2-oxo-cyclohex-3-enyl)-propionic acid methyl ester 

Relevant academic research and scientific papers

Enantiospecific syntheses of paeonilactone A, paeonilactone B, 7S-paeonimetabolin-I, and 7R-paeonimetabolin-I from R-(-)-carvone

The first enantiospecific syntheses of the title monoterpenes have been accomplished starting with R-(-)-carvone, which made their absolute structures unequivocal.

STEREOSELECTIVE SYNTHESIS OF THE PAEONILACTONES A, B AND C

The first total syntheses of the title monoterpenes are reported.